

DAFTAR PUSTAKA

- [1] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder Edition “DSM-5”. Washington DC: American Psychiatric Publishing; 2013.
- [2] World Health Organization. Mental disorders [Internet]; 2018. [diakses pada 13 November 2023]. Laman: <https://www.who.int/news-room/fact-sheets/detail/mental-disorders>
- [3] Kementerian Kesehatan RI. Laporan Nasional Riskesdas 2018 [Internet]; 2018. [diakses pada 13 November 2023]. Laman: <https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/>
- [4] Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. 2015;387(10027):1561–72.
- [5] Wahdi AE, Wilopo SA, Erskine HE. 122. The Prevalence of Adolescent Mental Disorders in Indonesia: An Analysis of Indonesia – National Mental Health Survey (I-NAMHS). J Adolesc Heal. 2023;72(3):S70.
- [6] Syafwan AF, Sedjahtera K, Asterina A. Gambaran Peningkatan Angka Kejadian Gangguan Afektif dengan Gejala Psikotik pada Pasien Rawat Inap di RSJ Prof. Dr. HB. Sa’anin Padang pada Tahun 2010 - 2011. J Kesehat Andalas. 2014;3(2):106–9.
- [7] Department of Veterans Affairs dan Department of Defense. Management of Bipolar Disorder in Adults (BD). US: The Management of Bipolar Disorder Working Group.
- [8] Geddes JR, Miklowitz DJ. Treatment of Bipolar Disorder. Lancet. 2013;381(9878):867–75.
- [9] Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD). 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
- [10] Nayak R, Rosh I, Kustanovich I, Stern S. Mood stabilizers in psychiatric disorders and mechanisms learnt from in vitro model systems. Int J Mol Sci. 2021;22(17):9315.
- [11] Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy. CNS Drugs. 2014;28:989–1003.
- [12] Zeng X. The discussion and analysis of the treatment of the bipolar disorder. In: 2022 4th International Conference on Literature, Art and Human Development (ICLAHD 2022). Atlantis Press. 2023;11–8.
- [13] Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry. 2008;69(SUPPL. 5):9–15.

- [14] Paulzen M, Gründer G, Benkert O. Medikamente zur Behandlung bipolarer Störungen. In: Benkert O, Hippus H, editors. *Kompandium der Psychiatrischen Pharmakotherapie*. 12th ed. Heidelberg/Berlin: Springer; 2019. p. 209–83.
- [15] Marzani G, Price Neff A. Bipolar Disorders: Evaluation and Treatment. *Am Fam Physician*. 2021;103(4):227–39.
- [16] Shareef J, Rao PGM, Al-Bonni IMA, Khudhaier R. Assessment of Drug related problems Encountered in Patients with Psychiatric disorders in a Secondary Care Hospital. *Res J Pharm Technol*. 2021;14(11):6089–94.
- [17] Pregelj P. Gene Environment Interactions in Bipolar Disorder. *Psychiatr Danub*. 2011;23(1):91–3.
- [18] Fries GR, Pfaffenseller B, Stertz L, Paz AVC, Dargél AA, Kunz M, et al. Staging and neuroprogression in bipolar disorder. *Curr Psychiatry Rep*. 2012;14(6):667–75.
- [19] Girshkin L, Matheson SL, Shepherd AM, Green MJ. Morning cortisol levels in schizophrenia and bipolar disorder: A meta-analysis. *Psychoneuroendocrinology*. 2014;49(1):187–206.
- [20] Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. *Br J Psychiatry*. 2004;184(6):496–502.
- [21] Ellenbogen MA, Santo JB, Linnen AM, Walker CD, Hodgins S. High cortisol levels in the offspring of parents with bipolar disorder during two weeks of daily sampling. *Bipolar Disord*. 2010;12(1):77–86.
- [22] Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. *Psychoneuroendocrinology*. 2009;34(SUPPL. 1):186–95.
- [23] Scammell JG, Denny WB, Valentine DL, Smiths DF. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. *Gen Comp Endocrinol*. 2001;124(2):152–65.
- [24] Craddock N, Jones I. Genetics of bipolar disorder. *J Med Genet*. 1999;36:585–94.
- [25] Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. *Arch Gen Psychiatry*. 2011;68(3):241–51.
- [26] Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. *Psychiatry Res [Internet]*. 2015;228(3):386–92.
- [27] Miller GE, Chen E, Sze J, Marin T, Arevalo JMG, Doll R, et al. A Functional Genomic Fingerprint of Chronic Stress in Humans: Blunted Glucocorticoid and Increased NF- κ B Signaling. *Biol Psychiatry*. 2008;64(4):266–72.
- [28] Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. *Mol Cell Neurosci*. 2013;53:52–62.
- [29] Barbosa IG, Bauer ME, MacHado-Vieira R, Teixeira AL. Cytokines in bipolar disorder: Paving the way for neuroprogression. *Neural Plast*. 2014;2014:360481.

- [30] Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N, et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. *Transl Psychiatry*. 2014;4(3):1–7.
- [31] Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. *Brain Behav Immu*. 2015;43:205–13.
- [32] Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the proinflammatory activities of IL-6. *Int J Biol Sci*. 2012;8:1237–47.
- [33] Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta - Mol Cell Res*. 2011;1813:878–88.
- [34] Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. *Blood*. 2007;110:1748–55.
- [35] Barkhausen T, Tschernig T, Rosenstiel P, Van Griensven M, Vonberg RP, Dorsch M, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. *Crit Care Med*. 2011;39(6):1407–13.
- [36] Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: A molecular switch to control inflammation and tissue regeneration. *Trends Immunol*. 2011;32:380–7.
- [37] Waetzig GH, Rose-John S. Hitting a complex target: An update on interleukin-6 trans-signalling. *Expert Opin Ther Targets*. 2012;16(2):225–36.
- [38] Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? *Expert Opin Ther Targets*. 2014;18(5):495–512.
- [39] Fonseka TM, McIntyre RS, Soczynska JK, Kennedy SH. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. *Expert Opin Investig Drugs*. 2014;24(3):459–75.
- [40] Bauer M, Pfennig A. Epidemiology of bipolar disorders. *Epilepsia*. 2005;46(SUPPL. 4):8–13.
- [41] Marwaha S, Sal N, Bebbington P. Chapter 9: Bipolar disorder. Leeds: NHS Digital; 2016.
- [42] Clemente AS, Diniz BS, Nicolato R, Kapczinski FP, Soares JC, Fermo JO, et al. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. *Rev Bras Psiquiatr*. 2015;37:155–61.
- [43] Fajutrao L, Locklear J, Priaux J, Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. *Clin Pract Epidemiol Ment Heal*. 2009;5:1–8.
- [44] Esan O, Esan A. Epidemiology and burden of bipolar disorder in Africa: a systematic review of data from Africa. *Soc Psychiatry Psychiatr Epidemiol*. 2016;51:93–100.

- [45] Idaiani S, Yunita I, Tjandrarini DH, Indrawati L, Darmayanti I, Kusumawardani N, et al. Prevalensi Psikosis di Indonesia berdasarkan Riset Kesehatan Dasar 2018. *J Penelit dan Pengemb Pelayanan Kesehat*. 2019;3(1):9–16.
- [46] McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, et al. Bipolar disorders. *The Lancet*. 2020;396(10265):1841–56.
- [47] [Craddock N, Sklar P. Genetics of bipolar disorder. *Lancet*. 2013;381:1654–62.](#)
- [48] Badner JA, Koller D, Foroud T, Edenberg H, Nurnberger Jr JI, Zandi PP, et al. Genome-wide linkage analysis of 972 bipolar pedigrees using single-nucleotide polymorphisms. *Mol Psychiatry*. 2012;17:818–26.
- [49] Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. *Ther Adv Psychopharmacol*. 2018;8(9):251–69.
- [50] Vieta E, Salagre E, Grande I, Carvalho AF, Fernandes BS, Berk M, et al. Early intervention in Bipolar disorder. *Am J Psychiatry*. 2018;175(5):411–26.
- [51] Gilman, SE, Dupuy JM, Perlis RH. Risks for the transition from major depressive disorder to bipolar disorder in the national epidemiologic survey on alcohol and related conditions. *J Clin Psychiatry*. 2012;73(6):829–36.
- [52] Tsuchiya KJ, Byrne M, Mortensen PB. Risk factors in relation to an emergence of bipolar disorder: A systematic review. *Bipolar Disord*. 2003;5(4):231–42.
- [53] Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: A systematic review and meta-analysis. *J Affect Disord*. 2015;171:39–47.
- [54] Van Laar M, Van Dorsselaer S, Monshouwer K, De Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? *Addiction*. 2007;102(8):1251–60.
- [55] Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet* [Internet]. 2016;387(10027):1561–72.
- [56] Harrison PJ, Cipriani A, Harmer CJ, Nobre AC, Saunders K, Goodwin GM, Geddes JR. Innovative approaches to bipolar disorder and its treatment. *Annals of the New York Academy of Sciences*. 2016;1366(1):76–89.
- [57] Phillips ML, Kupfer DJ. Bipolar Disorder 2 - Bipolar disorder diagnosis: Challenges and future directions. *Lancet*. 2013;381(9878):1663–71.
- [58] Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: Results of a long-term prospective study of hospital admissions. *J Affect Disord*. 2005;84(2–3):149–57.
- [59] Wang Y-Y, Xu D-D, Liu R, Yang Y, Grover S, Ungvari GS, et al. Comparison of the screening ability between the 32-item Hypomania Checklist (HCL-32) and the Mood Disorder Questionnaire (MDQ) for bipolar disorder: a meta-analysis and systematic review. *Psychiatry Res*. 2019;273:461–66.
- [60] Strakowski SM, Adler CM, Almeida J, Altshuler LL, Blumberg HP, Chang KD, et al. The functional neuroanatomy of bipolar disorder: a consensus model. *Bipolar Disord*. 2012;14(4):1–17.

- [61] Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: A meta-analysis of emotion activation studies in PET and fMRI. *Neuroimage*. 2002;16(2):331–48.
- [62] Phillips ML, Ladouceur C, Drevets WC. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. *Mol Psychiatry*. 2008;13(9):829–57.
- [63] Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J. Neurobiology of depression and bipolar disorder. *Neuropsychopharmacology*. 2007;33(1):1–16.
- [64] Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. *Biol Psychiatry*. 2008;54(6):504–14.
- [65] Belvederi Murri M, Pariante CM, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. The HPA axis in bipolar disorder: Systematic review and meta-analysis. *Psychoneuroendocrinology*. 2016;63:327–42.
- [66] Miziou S, Tsitsipa E, Moysidou S, Karavelas V, Dimelis D, Polyzoidou V, et al. Psychosocial treatment and interventions for bipolar disorder: A systematic review. *Ann Gen Psychiatry*. 2015;14(1):1–11.
- [67] Thase ME, Kingdon D, Turkington D. The promise of cognitive behavior therapy for treatment of severe mental disorders: A review of recent developments. *World Psychiatry*. 2014;13(3):244–50.
- [68] Ye BY, Jiang ZY, Li X, Cao B, Cao LP, Lin Y, et al. Effectiveness of cognitive behavioral therapy in treating bipolar disorder: An updated meta-analysis with randomized controlled trials. *Psychiatry Clin Neurosci*. 2016;70(8):351–61.
- [69] Chiang KJ, Tsai JC, Liu D, Lin CH, Chiu HL, Chou KR. Efficacy of cognitive-behavioral therapy in patients with bipolar disorder: A metaanalysis of randomized controlled trials. *PLoS One*. 2017;12(5):1–19.
- [70] Isasi AG, Echeburúa E, Limiñana JM, González-Pinto A. How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial. *J Affect Disord [Internet]*. 2010;126(1–2):80–7.
- [71] Zhong M, Wang X, Xiao J, Yi J, Zhu X, Liao J, et al. Amygdala hyperactivation and prefrontal hypoactivation in subjects with cognitive vulnerability to depression. *Biol Psychol*. 2011;88(2–3):233–42.
- [72] Young KD, Zotev V, Phillips R, Misaki M, Drevets WC, Bodurka J. Amygdala real-time functional magnetic resonance imaging neurofeedback for major depressive disorder: A review. *Psychiatry Clin Neurosci*. 2018;72(7):466–81.
- [73] Young KD, Siegle GJ, Zotev V, Phillips R, Misaki M, Yuan H, et al. Randomized clinical trial of real-time fMRI amygdala neurofeedback for major depressive disorder: Effectson symptoms and autobiographical memory recall. *Am J Psychiatry*. 2017;174(8):748–55.
- [74] Joas E, Bäckman K, Karanti A, Sparding T, Colom F, Pålsson E, et al. Psychoeducation for bipolar disorder and risk of recurrence and hospitalization-a within-individual analysis using registry data. *Psychol Med*. 2020;50(6):1043–9.

- [75] Crowe M, Porter R, Inder M, Carlyle D, Luty S, Lacey C, et al. Clinical effectiveness trial of adjunctive interpersonal and social rhythm therapy for patients with bipolar disorder. *Am J Psychother*. 2020;73(3):107–14.
- [76] Reinares M, Sánchez-Moreno J, Fountoulakis KN. Psychosocial interventions in bipolar disorder: What, for whom, and when. *J Affect Disord*. 2014;156:46–55.
- [77] Shah N, Grover S, Rao GP. Clinical Practice Guidelines for Management of Bipolar Disorder. *Indian J Psychiatry*. 2017;59(1):S51–S66.
- [78] Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. *Arch Gen Psychiatry*. 2005;62(9):996–1004.
- [79] Varghese M, Kirpekar V, Loganathan S. Family Interventions: Basic Principles and Techniques. *Indian J Psychiatry*. 2020;62(2):S192–S200.
- [80] Veeh J, Kopf J, Kittel-Schneider S, Deckert J, Reif A. Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. *Int J Bipolar Disord*. 2017;5(1).
- [81] Creswell JD. Mindfulness Interventions. *Annu Rev Psychol*. 2017;68:491–516.
- [82] Killingsworth MA, Gilbert DT. A wandering mind is an unhappy mind. *Science*. 2010;330(6006):932.
- [83] Slutsky J, Rahl H, Lindsay EK, Creswell JD. Mindfulness, Emotion Regulation, and Social Threat. *Mindfulness Soc Psychol*. 2017:79–93.
- [84] Chu CS, Stubbs B, Chen TY, Tang CH, Li DJ, Yang WC, et al. The effectiveness of adjunct mindfulness-based intervention in treatment of bipolar disorder: A systematic review and meta-analysis. *J Affect Disord*. 2018;225:234–45.
- [85] Burgos-Julián FA, Ruiz-Íñiguez R, Peña-Ibáñez F, Montero AC, Santed-Germán MA. Mindfulness-based and mindfulness-informed interventions in bipolar disorder: A meta-analysis based on Becker's method. *Clin Psychol Psychother*. 2022;29(4):1172–85.
- [86] Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. *Mol Psychiatry*. 2019;24(2):198–217.
- [87] Malhi GS, Bell E, Boyce P, Bassett D, Berk M, Bryant R, et al. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. *Bipolar Disorders*. 2020;22(8):805–82.
- [88] Solmi M, Veronese N, Zaninotto L, Van Der Loos MLM, Gao K, Schaffer A, et al. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: A comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. *CNS Spectr*. 2016;21(5):403–18.
- [89] Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. *Int J Bipolar Disord*. 2018;6(1).
- [90] Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A systematic review and network meta-analysis. *The Lancet Psychiatry*. 2014;1(5):351–9.

- [91] Shine B, Mcknight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: A retrospective analysis of laboratory data. *Lancet*. 2015;386(9992):461–8.
- [92] Tondo L, Abramowicz M, Alda M, Bauer M, Bocchetta A, Bolzani L, et al. Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. *Int J Bipolar Disord*. 2017;5(1).
- [93] Grunze A, Amann BL, Grunze H. Efficacy of carbamazepine and its derivatives in the treatment of bipolar disorder. *Med*. 2021;57(5):1–17.
- [94] Nie Q, Su B, Wei J. Neurological teratogenic effects of antiepileptic drugs during pregnancy. *Exp Ther Med*. 2016;12(4):2400–4.
- [95] Wells BG, Dipiro JT, Dipiro CV ST. *Pharmacotherapy Handbook*. Vol. 9. 2015. 1–965 p.
- [96] Rybakowski JK. Lithium—past, present, future. *Int J Psychiatry Clin Pract*. 2020;24(4):330–40.
- [97] Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. *Pharmacol Biochem Behav*. 2014;123:3–16.
- [98] Rybakowski JK. Mood Stabilizers of First and Second Generation. *Brain Sci*. 2023;13(5).
- [99] Schäfer M, Brandl EJ. Mood Stabilizers: Valproate. *NeuroPsychopharmacotherapy*. 2022;1549–57.
- [100] Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G. Discovery and development of lamotrigine for bipolar disorder: A story of serendipity, clinical observations, risk taking, and persistence. *J Affect Disord*. 2008;108(1–2):1–9.
- [101] Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of Add-on Treatment with Lamotrigine in Partial Epilepsy. *Epilepsia*. 1993;34(2):312–22.
- [102] Geddes JR, Gardiner A, Rendell J, Voysey M, Tunbridge E, Hinds C, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): A 2×2 factorial randomised trial. *The Lancet Psychiatry*. 2016;3(1):31–9.
- [103] Stahl SM, Morrisette DA, Faedda G, Fava M, Goldberg JF, Keck PE, et al. Guidelines for the recognition and management of mixed depression. *CNS Spectr*. 2017;22(2):203–19.
- [104] Besag FMC, Vasey MJ, Sharma AN, Lam ICH. Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review. *Ther Adv Psychopharmacol*. 2021;11:1–37.
- [105] Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Auby P. Aripiprazole in the treatment of acute manic or mixed episodes in bipolar I disorder: a placebo-controlled, 3-week study. *J Psychopharmacol*. 2006;20(4):536–46.
- [106] NICE. Bipolar disorder: assessment and management. *Aust Fam Physician*. 2014;36(4):1–47.

- [107] De Fruyt J, Deschepper E, Audenaert K. Safety and tolerability of aripiprazole: a review. *CNS Drugs*. 2012;26(7):549–65.
- [108] Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers. *J Clin Pharmacol*. 2004;44(2):179–87.
- [109] Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. *Cureus*. 2016;8(4).
- [110] Fornaro M, Carvalho AF, Fusco A, Anastasia A, Solmi M, Berk M, et al. The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. *J Affect Disord*. 2020;276:970–83.
- [111] Li X Bin, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: A systematic review. *Bipolar Disord*. 2015;17(3):235–47.
- [112] Meltzer HY. Update on typical and atypical antipsychotic drugs. *Annu Rev Med*. 2013;64:393–406.
- [113] Siskind D, MacCabe JH, Cohen D, Berecki-Gisolf J, McCartney L, Lappin JM, et al. Clozapine for treatment-resistant schizophrenia: A systematic review and meta-analysis. *Lancet Psychiatry*. 2021;8(4):293–306.
- [114] Zink M, Englisch S, Knopf U, Marneros A. Clozapine in the long-term treatment of severely ill bipolar patients with psychotic features. *Bipolar Disord*. 2004;6(6):548–56.
- [115] Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*. 2016;30(6):495–553.
- [116] Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology*. 1996;14(2):87–96.
- [117] Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden CL. Efficacy of olanzapine in combination with valproate or lithium in the treatment of bipolar I disorder. *Arch Gen Psychiatry*. 2002;59(1):62–69.
- [118] Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs*. 2005;19(S1):1–93.
- [119] McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey. *Can J Psychiatry*. 2006;51(5):274–80.
- [120] Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT_{1A} agonist, as a putative mediator of quetiapine's antidepressant activity. *Neuropsychopharmacology*. 2008;33(10):2303–12.

- [121] De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol*. 2012;8(2):114–26.
- [122] McElroy SL, Martens BE, Winstanley EL, Martens M, Keck PE Jr. A retrospective assessment of weight change patterns in acute and long-term treatment with quetiapine. *J Clin Psychiatry*. 2010;71(9):1124–30.
- [123] Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. *Biol Psychiatry*. 2010;68(2):156–62.
- [124] Schotte A, Janssen PF, Megens AA, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacology*. 1996;124(1–2):57–73.
- [125] Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. *Br J Psychiatry*. 2005;187(3):229–34.
- [126] Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. *Drugs*. 2004;64(20):2291–314.
- [127] Peuskens J, Sanger TM, Simpson GM, Lindenmayer JP, Schreiner A, Chouinard G. The effects of risperidone on prolactin levels and sexual functioning. *Schizophr Res*. 2000;41(2):189–96.
- [128] Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov*. 2004;3(4):353–9.
- [129] Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of olanzapine and ziprasidone in acute mania: a pilot study. *Bipolar Disord*. 2004;6(3):198–205.
- [130] Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. *CNS Drugs*. 2007;21(1):37–52.
- [131] Hugenholtz GW, Heerdink ER, Meijer WE, van Staa TP, Egberts AC. Risk of sudden cardiac death associated with antipsychotic use in dementia. *J Clin Psychopharmacol*. 2006;26(6):585–90.
- [132] Szegedi A, Durgam S, Mackle M, Yun Yu S, Wu X, Mathews M, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. *Am J Psychiatry*. 2018;175(1):71–9.
- [133] McIntyre RS, Brecher M, Paulsson B, Huizar K, Patel M. Asenapine treatment of bipolar I disorder: a 40-week open-label extension study. *Bipolar Disord*. 2010;12(3):298–310.
- [134] Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. *Life Sci*. 1995;57(5):411–41.

- [135] Shelton RC, Stahl SM. Fluoxetine and olanzapine combination for bipolar depression: a critical review. *Curr Psychiatry Rep.* 2004;6(6):452–8.
- [136] Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs GS, Bowden CL, et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry.* 2003;60(11):1079–88.
- [137] Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and SSRIs: systematic review of observational studies. *BMJ.* 2005;330(7488):396.
- [138] Divoll M, Greenblatt DJ, Ehrenberg BL, Shader RI. Pharmacokinetics and bioavailability of clobazam, a 1,5-benzodiazepine. *J Clin Pharmacol.* 1983;23(6–7):211–8.
- [139] Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos DJ, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. *N Engl J Med.* 2010;362(9):790–9.
- [140] McIntyre RS, Jerrell JM. Adjunctive benzodiazepine use in bipolar disorder: a clinical overview. *Curr Psychiatry Rep.* 2008;10(6):458–64.
- [141] Lader M. Benzodiazepines revisited—will we ever learn? *Addiction.* 2011;106(12):2086–109.
- [142] Chaves C, Marcolin MA, Hirata ES, Lafer B. Use of clonazepam and clobazam in patients with bipolar disorder. *Braz J Psychiatry.* 2014;36(3):259–61.
- [143] World Health Organization. Promoting rational use of medicines: core components. WHO Policy Perspectives on Medicines. 2002.
- [144] Kementerian Kesehatan RI. Modul penggunaan obat rasional. Jakarta: Direktorat Bina Pelayanan Kefarmasian; 2011.
- [145] Rifaya A, Agustina R, Rusli R. Pola Penggunaan Obat Mood Stabilizer Pada Pasien Bipolar di Rumah Sakit Jiwa Daerah Atma Husada Mahakam. *Proc Mul Pharm Conf.* 2019;10:86–93.
- [146] Meinhard M, Kessing LV, Vinberg M. The role of estrogen in bipolar disorder: a review. *Nord J Psychiatry.* 2012;68(2):81–7.
- [147] Agustin A. Gambaran karakteristik pasien bipolar di rumah sakit jiwa provinsi kalimantan barat. *J Mhs Farm Fak Kedokt UNTAN.* 2020;4(1).
- [148] Angst J, Paksarian D, Cui L, Merikangas KR, Hengartner MP, Ajdacic-Gross V, et al. The epidemiology of common mental disorders from age 20 to 50: Results from the prospective Zurich cohort Study. *Epidemiol Psychiatr Sci.* 2015;25(1):24–32.
- [149] Anggraeni MD, Agustina R, Indriyanti N. Pola Penggunaan Obat Antikonvulsan pada Pasien Gangguan Kejiwaan di Rumah Sakit Jiwa Daerah Atma Husada Mahakam Samarinda. *Proc Mul Pharm Conf.* 2019;10:48–51.
- [150] Sarfiyenti A, Prawita E. Gangguan Mental Bipolar pada Remaja yang Dapat Mengubah Mood Secara Drastis. 2024;10(14). (artikel)
- [151] Lantu GN, Ginting HB, Pantow S, Syaloom G, Ninda HS, Sengkey SB, et al. Gangguan Bipolar pada Remaja. *Jurnal Psikologi AFEKSI.* 2024;3(4):267–75.

- [152] Ayano G. Bipolar Disorders and Valproate: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Valproate: Review of Articles. *Bipolar Disord.* 2016;2(2).
- [153] Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. *Int J Bipolar Disord.* 2018;6(1).
- [154] Trengginas GT, Hasmono D, Subagyo R. Effects of Valproate and Fluoxetine Combination on YMRS and MADRS Scores in Continuation Phase Treatment of Bipolar Disorder. *Folia Medica Indones.* 2018;54(4):234.
- [155] Sohel AJ, Shutter MC, Patel P, et al. Fluoxetine [Internet]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [updated 2024 Feb 28; cited 2025 Jun 23].

